Laekna, Inc. (SEHK: 2105)
Health Care · Biotechnology · CN
HK$7.00
-0.21% today · -60.0% 1Y
Laekna, Inc. (SEHK: 2105) operates in the Biotechnology industry within the Health Care sector. The company is valued at $377.70M and employs 83 people.
Over the last twelve months the share price has lost 60.0%, trading between 5.37 and 20.32.
Tweenvest scores Laekna, Inc. across four factors: quality 32/100, value 62/100. Its strongest factor is value.
2105 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $377.70M
- Revenue (TTM)
- $15.26M
- P/E
- —
- EPS
- -0.59
- Dividend yield
- —
- Beta (5Y)
- -1.01
- 52-week high
- HK$20.32
- 52-week low
- HK$5.37
- Avg volume (3M)
- —
- Shares outstanding
- 423.42M
- Employees
- 83
- Next earnings
- —
About Laekna, Inc.
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE111, LAE112, LAE113, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.
- ISIN
- KYG5340S1093
- Founded
- 2016
- Listed since
- Jun 28, 2023
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.18 | +0.63% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.43 | +0.13% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $147.80 | +0.72% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $554.22 | +1.21% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $835.53 | +0.85% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.58 | +13.46% |
Figures last refreshed Aug 18, 2026.